Locked $ Loaded :
X 1. Cash Flow Positive Status - 4 + years
X 2. Purchase building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirkov, Doug and the Team
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023 First to File Aug 17, 2023
__12. Generate revenues over $20 million/quarter
__13. Generic OxyContin Approval - $720 Million IMS market
__14. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 15. Lease additional manufacturing and storage space for new ANDAs Jan 2024 - 34,000 square foot 18+ ft ceilings
__16. European distribution Dexcel partnership approval by Israeli Health
__17. Full ownership of Adderall IR $ 335 Million
__18. Full ownership of Adderall XR $ 1.56 Billion
__19. Generic Concerta- $1.2 BILLION FDA submission
__20. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__21. $100 million in yearly revenues
__22. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__23. Patented Unique ADF (w/o naltrexone)-- NDA
__24. Mikah ANDA (s)
__25. Undisclosed ANDAs/NDAs
__26. Antimetabolite ANDA- Methotrexate -$600 Million
__27. Undisclosed Antimetabolite ANDA- $42 Million
__28. Generic Vyvanse Approval
__29. DollarLand PPS
__30. Uplist to the NASDAQ Exchange
__31. THE Buy Out ! 2.0-2.5 yrs from Feb 2024
__32. Vegas Baby !!!!!!! 2.5 yrs
X 33. PE under 8
Bullish
